Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024. In the quarter to June 2026, revenue grew 2.68%, EPS was flat, free cash flow grew 13.6% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

99.70 0.29 −0.29%
Market cap
$6.5B
P/E
23.7×
Fwd P/E
25.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
10.41 6.38 14.76 25.32 0.00 0.00 123.59 13.20 19.79 19.35
Piotroski F-Score
6 6 6 4 3 5 7 7 5 5
P/S ratio
0.94 2.36 1.74 2.30 2.15 4.59 3.71 3.32 4.04 2.91
Altman Z-Score
0.86 2.13 2.09 2.77 1.51 3.03 3.38 5.32 6.67 4.25
P/FCF ratio
5.37 20.35 14.23 13.71 186.20 33.85 13.08 12.08 12.82 12.69
Altman Z″-Score (non-manufacturers)
(1.34) 0.93 2.07 1.90 1.71 1.02 2.38 6.34 7.16 4.61
Beneish M-Score
(2.87) (1.15) (2.62) (3.02) (1.68) (2.83) (2.79) (2.08) (2.97) (2.23)
P/Operating CF
22.19 59.82 34.57 35.67 1,283.42 140.38 32.94 38.36 39.25 49.81
P/B ratio
0.00 33.61 8.43 6.98 1.42 4.20 7.76 5.28 5.69 4.12
Price to Tangible BV
0.00 0.00 12.96 7.45 9.18 35.62 49.10 7.15 7.16 35.23
EV/Sales
1.69 2.94 2.19 2.59 2.56 4.76 3.86 3.21 3.81 3.05
EV/EBITDA
6.68 13.45 9.43 13.64 42.17 0.00 42.32 9.69 11.11 12.20
EV/Operating CF
10.28 17.79 12.28 11.21 53.00 37.58 12.82 13.62 10.73 12.05
EV/FCF
9.66 25.34 17.86 15.44 221.58 35.17 13.62 11.66 12.10 13.28
Quick Ratio
2.01 2.49 2.98 2.06 1.66 2.08 2.54 5.33 5.16 2.20
Current Ratio
2.53 3.16 3.70 2.62 2.29 2.61 2.74 5.80 5.52 2.70
Net Debt/EBITDA
2.97 2.65 1.92 1.53 6.73 (4.27) 1.67 (0.35) (0.66) 0.55
Debt/Assets
108.68% 69.85% 60.58% 47.81% 25.11% 20.23% 42.24% 34.07% 28.59% 25.56%
Debt/Equity
(2.61) 11.51 3.75 1.69 0.42 0.38 1.25 0.69 0.52 0.52
Asset Turnover
1.21 1.04 0.83 0.82 0.53 0.49 0.86 0.87 0.84 0.73
Operating CF/Net income
1.85 0.44 1.51 2.54 (1.22) (0.76) 10.04 0.93 1.74 1.67
Capex/Depreciation
0.16 (0.79) (1.26) (1.54) (0.50) 0.09 (0.34) 0.80 (0.90) (0.48)
Interest Coverage
2.13 2.82 3.71 3.79 (0.44) (7.85) 5.04 18.21 23.23 15.74
ROE
(18.34%) (296.51%) 85.94% 34.12% (4.29%) (14.57%) 6.16% 51.73% 32.82% 21.45%
ROA
10.74% 38.57% 9.84% 7.49% (2.11%) (8.22%) 2.57% 21.98% 17.21% 11.10%
ROIC
29.37% 15.06% 17.99% 14.97% (0.40%) (7.03%) 3.84% 34.28% 38.52% 14.94%
Return on Tangible Assets
16.61% 63.57% 16.17% 14.18% (6.02%) (27.20%) 5.08% 31.25% 24.74% 31.98%
Average Days of Receivables
44.52 44.34 46.51 45.74 58.07 76.69 83.30 80.04 78.39 88.56
Research and Development Expense of Revenue
4.04% 5.47% 4.97% 5.76% 9.66% 10.58% 33.33% 5.99% 10.96% 11.50%
Selling, General and Administrative Expense of Revenue
24.97% 27.81% 27.18% 29.69% 32.46% 51.46% 25.01% 20.61% 24.23% 29.44%
Intangible Assets out of Total Assets
0.12 0.07 0.06 0.02 0.50 0.47 0.28 0.13 0.11 0.43
Share Based Compensation of Revenue
0.84% 1.79% 2.54% 3.60% 4.15% 3.75% 3.13% 3.90% 4.98% 5.55%
Graham Net Nets
(0.89) (0.27) (0.29) (0.15) (0.23) (0.08) (0.06) 0.06 0.07 (0.05)
Graham Number
0.00 6.80 6.66 7.32 0.00 0.00 7.76 35.85 39.99 35.35
Earnings Yield
9.60% 15.67% 6.77% 3.95% (1.70%) (3.63%) 0.81% 7.58% 5.05% 5.17%
Free Cash Flow Yield
18.64% 4.91% 7.03% 7.29% 0.54% 2.95% 7.64% 8.28% 7.80% 7.88%
Revenue per Share
9.42 8.89 8.98 8.91 6.27 6.30 13.65 18.99 22.17 22.84
Operating CF per Share
1.55 1.47 1.60 2.06 0.30 0.80 4.11 4.47 7.87 5.78
Capex per Share
0.10 (0.44) (0.50) (0.57) (0.23) 0.05 (0.24) 0.75 (0.89) (0.53)
Free Cash Flow per Share
1.65 1.03 1.10 1.50 0.07 0.85 3.87 5.22 6.98 5.25
Cash per Share
1.60 2.05 2.97 2.38 1.47 1.46 6.07 10.45 13.19 5.32
Shareholders Equity per Share
(3.32) 0.62 1.86 2.94 9.50 6.88 6.53 11.95 15.72 16.15
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(3.32) 0.62 1.86 2.94 9.50 6.88 6.53 11.95 15.72 16.15
Free Cash Flow
52.85 38.47 42.06 58.32 3.92 57.60 265.23 356.54 482.89 354.05
Working Capital
66.98 101.10 142.66 106.80 103.72 145.29 429.92 898.47 1,086.11 566.55
Capital Expenditures
3.21 (16.31) (19.13) (22.06) (12.47) 3.68 (16.55) 51.28 (61.86) (36.09)
Net Current Asset Value
(251.59) (212.72) (173.41) (118.41) (171.39) (163.55) (196.49) 250.56 434.30 (237.64)
EV/EBIT
9.02 18.80 11.65 17.44 0.00 0.00 99.81 11.40 12.79 15.13
Capex to Sales
(0.01) 0.05 0.06 0.06 0.04 (0.01) 0.02 (0.04) 0.04 0.02
Price to Operating Income
5.01 15.10 9.28 15.48 0.00 0.00 95.88 11.81 13.55 14.45
Other line items
Depreciation/Fixed assets
0.21 0.22 0.14 0.12 0.21 0.37 0.40 0.44 0.39 0.46
Cash ROIC
23.72% 10.46% 9.33% 14.52% 0.48% 7.81% 18.67% 17.04% 18.81% 17.54%
Accounts Receivable Turnover
8.15 8.60 8.17 7.96 6.96 5.93 6.18 5.21 5.00 4.38
Accounts Payable Turnover
10.72 9.30 9.51 9.44 11.50 12.81 17.09 19.01 14.41 15.48
Inventory Turnover
9.87 7.74 5.70 5.55 6.18 6.70 10.01 11.80 8.26 9.04
Average Days of Payables
42.13 37.66 38.90 39.37 29.62 31.94 21.24 25.62 23.12 26.12
Days of Inventory on Hand
39.24 56.25 71.53 61.73 65.02 53.98 36.64 39.82 45.51 39.37
Average Receivables
37.06 38.54 42.01 43.64 48.77 71.67 151.37 248.84 306.86 351.73
Average Payables
15.30 18.20 17.71 18.28 17.45 18.54 20.68 30.88 37.87 38.73
Average Inventory
16.63 21.86 29.55 31.10 32.46 35.44 35.30 49.75 66.03 66.35
Average Assets
249.14 319.88 411.84 422.88 637.87 866.80 1,092.52 1,486.20 1,815.74 2,103.87
Average Common Equity
(145.90) (41.61) 47.15 92.80 314.40 489.32 455.79 631.52 951.95 1,088.90

Fold the line items

Columns are period end dates